Quantum BioPharma develops drug candidates for neurodegenerative, inflammatory, metabolic and alcohol misuse disorders. QNTM reports earnings on Fri, Nov 6, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 31 | Rodman & Renshaw | Initiated | Buy |
Seasonality
How QNTM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in QNTM in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QNTM is in one of them and how their past QNTM trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered QNTM in an article yet. Here's the latest on the wider market.
About Quantum Biopharma
Quantum BioPharma is a biopharmaceutical company based in Toronto that develops drug candidates for neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse. Its lead candidate, Lucid-MS, is being researched as a possible treatment for multiple sclerosis and is at the preclinical stage. The company has also licensed unbuzzd, a dietary supplement drink intended for people who have consumed excess alcohol, to Unbuzzd and Celly U.S. for retail sale. It is also developing a healthcare product for use in hospitals and emergency departments.
- Headquarters
- Toronto